Finance

Lists
Why is GXE up 2,98%?
Dive Deeper
GXE:ETR
Lakefront Biotherapeutics NV
26,92 €
+2,98%
(+0,78) 1D
15 հոկ, 17:35:50 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GXE...
Open
26,06 €
High
26,96 €
Low
26,06 €
Mkt. cap
1,72 մլրդ
Avg. vol.
602,00
Volume
1,73 հզր
P/E ratio
2,98
52-wk high
30,02 €
52-wk low
22,84 €
EPS
9,05 €
No. of employees
196
Open
26,06 €
High
26,96 €
Low
26,06 €
Mkt. cap
1,72 մլրդ
Avg. vol.
602,00
Volume
1,73 հզր
P/E ratio
2,98
52-wk high
30,02 €
52-wk low
22,84 €
EPS
9,05 €
No. of employees
196
News stories
From web sources and news partners
Profile
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
About Lakefront Biotherapeutics NV
CEOPaul Stoffels | Paul Stoffels
Employees196
Founded1999
Headquarters-
Sector-
Last report
11 օգս, 2026 թ.
Fiscal period
Q2 2026
0,03 € / -11,50 €
+100,26%beat
Revenue / Est. (EUR)
12,11 մլն / 6,13 մլն
+97,55%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
71,16 մլն
900,82 մլն
6,48 մլն
12,11 մլն
Cost of goods sold
84,73 մլն
107,97 մլն
35,76 մլն
34,67 մլն
Cost of revenue
84,73 մլն
107,97 մլն
35,76 մլն
34,67 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34,55 մլն
32,29 մլն
35,50 մլն
22,50 մլն
Operating expense
28,10 մլն
170,00 հզր
34,42 մլն
20,95 մլն
Total operating expenses
112,83 մլն
108,14 մլն
70,18 մլն
55,62 մլն
Operating income
-41,67 մլն
792,68 մլն
-63,70 մլն
-43,51 մլն
Other non operating income
-51,21 մլն
74,15 մլն
959,00 հզր
223,00 հզր
EBT including unusual items
-221,49 մլն
783,16 մլն
13,96 մլն
2,01 մլն
EBT excluding unusual items
-43,59 մլն
835,73 մլն
-26,04 մլն
-14,75 մլն
Income tax expense
-17,50 մլն
666,00 հզր
70,00 հզր
70,00 հզր
Effective tax rate
7,90%
0,09%
0,50%
3,48%
Other operating expenses
-6,44 մլն
-32,12 մլն
-1,08 մլն
-1,55 մլն
Net income
-202,11 մլն
782,15 մլն
14,49 մլն
2,11 մլն
Net profit margin
-284,02%
86,83%
223,61%
17,42%
Earnings per share
-0,18
12,27
0,21
0,03
Interest and investment income
9,91 մլն
14,94 մլն
12,90 մլն
12,11 մլն
Interest expense
-
-1,03 մլն
-
-127,00 հզր
Net interest expenses
9,91 մլն
13,90 մլն
12,90 մլն
11,98 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,23 մլն
800,91 մլն
-55,48 մլն
-41,99 մլն
Gain or loss from assets sale
23,83 մլն
-1,06 մլն
-
-
AI content may include mistakes. Learn more
Google Apps